Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Adamis Pharmaceuticals Corporation
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with histopathologically proven adenocarcinoma of the prostate
Patients must have progressive disease
Patients must have had prior treatment with bilateral orchiectomy or androgen deprivation therapy with an LHRH-blocker with evidence of treatment failure
You may not be if
Patients treated with other secondary hormonal therapies
Patients with prior chemotherapy given for castrate-resistant prostate cancer
Patients with prior radiation therapy completed less than 4 weeks prior enrollment
Patients with prior investigational therapies within 4 weeks before treatment with APC-100
